Keywords: bi, genentech, terminate, tnkase/metalyse, trial, german, drugmaker
BI and Genentech terminate TNKase/Metalyse trial
Article | 18 July 2005
German drugmaker Boehringer Ingelheim and US biotechnology major Genentech have terminated their randomized, open-label Phase IIIb/IV clinical study of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
